From Discovery to Lead Optimization

We are currently in the early pre-clinical stage, transitioning towards a focused clinical pipeline. Our journey began with a proprietary library of 200+ novel molecules, which we systematically screen to identify the most promising antifungal candidates.

Milestones Achieved

• Proven Efficacy (Proof of Concept): We have identified several high-potential lead candidates that demonstrate potent antifungal activity. Crucially, these leads have proven effective against resistant Aspergillus fumigatus, one of the most challenging pathogens.

• Established Safety Profile: Rigorous in-vitro safety testing against human cell lines has been completed for our leads. This confirmed a favorable therapeutic index, showing no significant toxicity to human cells while maintaining lethal pressure on fungal pathogens.

Next Steps: Identifying the Primary Lead

Our current focus is the final selection of our top lead candidate. Through advanced pharmacokinetic (PK) and pharmacodynamic (PD) modeling, we are identifying the molecule with the optimal balance of tissue penetration, safety, and broad-spectrum potency to move forward into formal regulatory development and clinical trials.